At Pharmapack 2023, the Sanner Group is presenting its new strategy centered on two key pillars: an increasing emphasis as a device CDMO (contract development and manufacturing organization) for medical technology, diagnostics, and pharma drug delivery solutions, as well as a continuous drive of the core business as a reliable partner for desiccant solutions for the pharma and healthcare markets.
Sanner is known for its core business, delivering high-quality primary packaging solutions for pharmaceuticals, dietary supplements, and probiotics. The 2023 edition of Pharmapack will be held at Paris Expo Porte de Versailles, Department de Paris, France on 1 and 2 Feb 2023. Sanner will be present at booth B066.
“Sanner is a world market leader in the effervescent packaging segment. We are known for high quality and excellent service in desiccants and primary packaging,” says Johannis Willem van Vliet, CEO of the Sanner Group. “Customers from the pharmaceutical and healthcare industries can continue to rely on us. We remain focused on expanding our portfolio of tubes, closures, and drop-in solutions with new products being launched in 2023.”
Single source solutions
With years of desiccant and injection molding expertise, Sanner offers complete solutions from a single source, especially for moisture-sensitive drug-device combination products. “With our significant experience and know-how as an industrial design and development partner to our customers, we are well placed to deliver on the new strategic orientation in all the key global regions,” says van Vliet.
Focus as device CDMO
Sanner has been delivering device CDMO services for international customers in Europe, Asia, and the US for several years and has successfully implemented numerous projects. The reputation of the Sanner Group in this environment has grown steadily and is characterized by the experienced, agile, and reliable development and implementation of customer projects and manufacturing with the highest quality standards. The company is now focusing on expanding this business segment.
From the conception of the devices to the design and production of prototypes, the Sanner IDP-Process, a flexible and standardized stage-gate process, provides customers with full support in the development phase of a device. For prototyping, Sanner uses additively manufactured injection molding tools to quickly provide detailed visual samples made from the original material. The experienced industrial engineering team handles implementation with the development of automation and assembly concepts through to box-build logistics solutions or sterilization concepts. During industrialization and market introduction, customers benefit from Sanner’s excellent quality and an OTIF level of 99%.
Strengthened management team
Sanner has strengthened its existing management team to set the business up for future success, with the following key additions.
Christian Classen, who is responsible for sales, marketing, and product management joined as Chief Sales Officer (CSO) in October 2022 and will play an active role in delivering the enhanced strategic focus.
Henrik Boggild, who joined as Chief Financial officer (CFO) in September 2022, is responsible for finance, controlling, purchasing, and IT.
Together with Ralf Tiemann, the long-standing CEO of Sanner Asia-Pacific and Johannis Willem van Vliet, CEO of the Sanner Group, Classen and Boggild complete the Sanner management team.
“With these strategic and personnel moves, we are ideally positioned for the future,” van Vliet concludes. “We look forward to showing the new strategy and its possibilities, along with our extensive service portfolio, at Pharmapack.”